Morgan Cheatham serves as a Partner and Head of Healthcare and Life Sciences at Breyer Capital, a global venture firm. In this role, he leads investments in healthcare and life sciences, with a specific focus on applying computation to medicine. Breyer Capital's portfolio includes companies such as OpenEvidence, Abridge, ArteraAI, Iterative Health, Atropos Health, and Cleerly.

Prior to joining Breyer Capital, Cheatham was a Vice President at Bessemer Venture Partners.